Handbook of Clinical medicine

er stroke prevention therapy in patients with AF if <65y and CHA2DS2VASC score is 0 for men or 1 for women. • Anticoagulation (see p350) can be commenced 2wks after a stroke (or from 7–10d if clinically and radiologically small). Off er a direct oral anticoagulant (DOAC) or warfarin (p350), following a discussion of risks and benefi ts. Other cardiac sources of emboli: • Cardioversion. • Prosthetic valves. • Acute myocardial infarct with large left ventricular wall motion abnormalities on echocardiography. • Patent foramen ovale/septal defects. • Cardiac surgery. • In- fective endocarditis (gives rise to septic emboli; 20% of those with endocarditis present with CNS signs). Antiplatelets: mechanism of action Aspirin: Inhibits COX-1, suppressing prostaglandin and thromboxane synthesis. Clopidogrel: A thienopyridine that inhibits platelet aggregation by modifying platelet ADP receptors, preventing further strokes and MIS. Dipyridamole: CAMP and thromboxane A2. (a) (b) (c) (d) Fig 10.16 Categorization of pressure ulcers. (a) Stage 1: non-blanchable redness of intact skin, typically over a bony prominence. (b) Stage 2: partial thickness loss of dermis presenting as a shal- low open ulcer with a red/pink wound bed, without slough. May also present as an intact or open/ ruptured sero-sanguinous blister. (c) Stage 3:
